Philippe Moreau, MD, University Hospital of Nantes, Nantes, France, discusses the key points from his session on transplant-eligible patients during EMMA 2017. He answers some key clinical questions for us. Should we perform intense treatment and stem cell transplant systematically in patients under 65–70 years of age? What is the best induction therapy to use now, and how will our approach change in coming years? And what about consolidation – we've seen conflicting data here? Finally, he provides an update on the ongoing studies to determine strategies for maintenance therapy.
Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This programme was sponsored by Celgene through an unrestricted educational grant to Magdalen Medical Publishing.
